Recent Publications or news items

[drc007]

We ignore the disaster in the antibiotics market at our peril Financial Times article on economics of Antibiotic Research.

[drc007]

Now free access at Wellcome

https://wellcome.ac.uk/news/we-ignore-disaster-antibiotics-market-our-peril

[drc007]

In the review repository

March 29 2019 Needham Review.pdf Antibiotic R&D Update 20. Link.

Tackling antimicrobial Resistance 2019-2024, the UK's five-year national action plan.(Published 24 January 2019) Link

[mattodd]

Great idea to start this. I'd hope we might aggregate these into the wiki area about the literature around AMR etc, but this acts as a useful place to jot things down as they arise.

[drc007]

NO TIME TO WAIT: SECURING THE FUTURE FROM DRUG-RESISTANT INFECTIONS REPORT TO THE SECRETARY-GENERAL OF THE UNITED NATIONS APRIL 2019 Link

[drc007]

Five-Year Analysis Shows Continued Deficiencies in Antibiotic Development Visualization tool lets users track the pipeline from 2014 to 2018 https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2019/five-year-analysis-shows-continued-deficiencies-in-antibiotic-development

[drc007]

CO-ADD is a non-for-profit initiative led by academics at The University of Queensland. Our goal is to screen compound for antimicrobial activity for academic research groups and generate a public knowledge database for the development of novel agents for the treatment of microbial infections. The knowledge base contains chemical structures and antimicrobial activity data from CO-ADD’s screening, made publicly available by the academic research groups, with more data to be released over time. https://db.co-add.org/screening-data/

[drc007]

Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread https://www.bbc.co.uk/news/health-49132425 https://www.nature.com/articles/s41564-019-0492-8

[drc007]

Bacteria which are resistant to antibiotics has been found within the tonnes of sewage dumped into the River Thames. https://www.bbc.co.uk/news/av/uk-england-london-49435120/antibiotic-resistant-bacteria-found-in-river-thames

[drc007]

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

From EARS-Net data collected between Jan 1, 2015, and Dec 31, 2015, we estimated 671689 (95% uncertainty interval [UI] 583148–763966) infections with antibiotic-resistant bacteria, of which 63·5% (426277 of 671689) were associated with health care. These infections accounted for an estimated 33110 (28480–38430) attributable deaths and 874541 (768837–989068) DALYs. The burden for the EU and EEA was highest in infants (aged <1 year) and people aged 65 years or older, had increased since 2007, and was highest in Italy and Greece

Link

[drc007]

Call for Papers: Antibiotics Special Issue DOI.

To highlight new advances in antibiotic development, ACS Infectious Diseases and ACS Pharmacology & Translational Science will publish a joint Special Issue on the topic in mid-2020. Succinctly entitled “Antibiotics”, the Special Issue welcomes research from academics, not-for-profits, and industry on research related to the discovery and development of new antibiotics and antibiotic potentiators, submitted as Articles, Letters, Reviews, Viewpoints, and Perspectives. Ideally, this issue will provide a sampling of the different approaches to new antibiotic development, including advances based on the more traditional pathways of improving existing classes of antibiotics, rediscovering “lost” antibiotics from decades ago, and potentiating existing antibiotics to rescue them from obsolescence. We strongly encourage the submission of research featuring promising new chemotypes acting on novel targets: the Holy Grail of antibiotic discovery. While new antimicrobials based on novel modalities have proven to be exceedingly difficult to advance all the way to drug approval, substantial advances have been made with programs such as LpxC inhibitors.

[drc007]

Drug-resistant infections: the science is on track, but the economics need fixing. https://wellcome.ac.uk/what-we-do/our-work/drug-resistant-infections/drug-resistant-infections-science-economics?utm_source=twitter&utm_medium=ad-wellcome&utm_campaign=dri_market_incentives&utm_content=pharma-image-infographic

[drc007]

How to communicate about antimicrobial resistance effectively https://wellcome.ac.uk/reports/reframing-antimicrobial-resistance-antibiotic-resistance

[mattodd]

Super interesting NHS trial that is compatible with open source. Must add to e.g. wiki sources summarising funding mechanisms/ideas.

New antibiotics: NHS will test “pay for usefulness” model to stimulate research BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4610 (Published 09 July 2019) Cite this as: BMJ 2019;366:l4610 https://www.bmj.com/content/366/bmj.l4610 "The NHS will pay drug companies up front for access to new drugs depending on their usefulness, in an effort to encourage them to invest the £1bn (€1.11bn; $1.25bn) or more needed to bring a new antibiotic to market..."

[drc007]

Drug-resistant infections: transforming the global response

We want to transform the world's approach towards stemming the rise and spread of drug-resistant infections. Antibiotics are a vital part of modern medicine but their overuse and inappropriate use in humans and animals has caused one of the most urgent global health problems.

https://wellcome.ac.uk/what-we-do/our-work/drug-resistant-infections?utm_source=twitter&utm_medium=o-wellcome

[mattodd]

Not sure where to put this, if we've not already inserted in to one of the wikis:

Lamoree, B., & Hubbard, R. E. (2018). Using Fragment-Based Approaches to Discover New Antibiotics. SLAS DISCOVERY: Advancing Life Sciences R&D, 23(6), 495–510. https://doi.org/10.1177/2472555218773034

https://journals.sagepub.com/doi/10.1177/2472555218773034

[mattodd]

The global preclinical antibacterial pipeline Ursula Theuretzbacher, Kevin Outterson, Aleks Engel & Anders Karlén Nature Reviews Microbiology (2019) doi:10.1038/s41579-019-0288-0 https://www.nature.com/articles/s41579-019-0288-0

[drc007]

Governments must make tackling AMR worth pharmacy's while.

Antimicrobial resistance (AMR) is expected to kill 10 million people by 2050

https://www.pharmaceutical-journal.com/news-and-analysis/opinion/comment/governments-must-make-tackling-amr-worth-pharmacys-while/20207378.article?firstPass=false

[drc007]

Setting Our Sights on Infectious Diseases. In May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. ACS Infect. Dis (open access). Link

[drc007]

Biopharma has abandoned antibiotic development. Here’s why we did, too by Isaac Stoner Octagon Therapeutics https://endpts.com/biopharma-has-abandoned-antibiotic-development-heres-why-we-did-too/

[drc007]

Crisis Looms in Antibiotics as Drug Makers Go Bankrupt https://www.nytimes.com/2019/12/25/health/antibiotics-new-resistance.html

At a time when germs are growing more resistant to common antibiotics, many companies that are developing new versions of the drugs are hemorrhaging money and going out of business, gravely undermining efforts to contain the spread of deadly, drug-resistant bacteria.

Antibiotic start-ups like Achaogen and Aradigm have gone belly up in recent months, pharmaceutical behemoths like Novartis and Allergan have abandoned the sector and many of the remaining American antibiotic companies are teetering toward insolvency. One of the biggest developers of antibiotics, Melinta Therapeutics, recently warned regulators it was running out of cash.

[drc007]

Drug-resistant infections: the science is on track, but the economics need fixing https://wellcome.ac.uk/what-we-do/our-work/drug-resistant-infections/drug-resistant-infections-science-economics?utm_source=twitter&utm_medium=o-wellcome&utm_campaign=marketsquote

There were antibiotics that I was using when I first came into practice, and we were confident they would treat most infections. The resistance to those antibiotics is now very significant, about 30% in some regions in the UK

[drc007]

One in five deaths around the world is caused by sepsis ..... the report estimates 11 million people a year are dying from sepsis - more than are killed by cancer.

https://www.bbc.co.uk/news/health-51138859

[drc007]

‘If grippe condemns, the secondary infections execute’: What the coronavirus pandemic means for the field of antibiotics An analysis of postmortem samples from the “Spanish flu” pandemic of 1918 to 1919 highlighted that secondary bacterial infections caused the majority of deaths.

https://endpts.com/if-grippe-condemns-the-secondary-infections-execute-what-the-coronavirus-pandemic-means-for-the-field-of-antibiotics/

[drc007]

This webinar provided an overview and update on GARDP’s efforts to bring new antibiotic treatments for drug-resistant infections to all who need them.

The following topics were presented:

• Antibiotic resistance and the GARDP response
• Tackling the growing threat of hospital infections
• Developing new treatments for neonatal sepsis

https://youtu.be/kHig7P-ohO8

[drc007]

Why big pharma has abandoned antibiotics A lack of financial incentive has meant large pharmaceutical companies have left the market https://www.nature.com/articles/d41586-020-02884-3

[drc007]

The silent pandemic of antibiotic resistance A South African doctor’s prescription to stop poorer countries losing access to many of modern medicine’s advances https://www.ft.com/content/520b0300-1717-4f66-b792-f2f7da7112a3

[mattodd]

Miethke, M., Pieroni, M., Weber, T. et al. Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem 5, 726–749 (2021). https://doi.org/10.1038/s41570-021-00313-1 https://www.nature.com/articles/s41570-021-00313-1

Laura J V Piddock, Jean-Pierre Paccaud, Seamus O’Brien, Michelle Childs, Rohit Malpani, Manica Balasegaram, A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution, Clinical Infectious Diseases, 2021;, ciab887, https://doi.org/10.1093/cid/ciab887 https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab887/6383425

[drc007]

GARDP study reveals that babies are increasingly dying of neonatal sepsis caused by drug-resistant bacterial infections https://gardp.org/news-resources/gardp-study-reveals-that-babies-are-increasingly-dying-of-neonatal-sepsis-caused-by-drug-resistant-bacterial-infections/

[mattodd]

Nice article on the subscription model https://www.bcg.com/publications/2022/model-for-tackling-antimicrobial-resistance